Hematology practice marketing: anemia claims

A hematology practice gets patients in a way few specialties do: a primary care doctor, an obstetrician or a surgeon finds a low blood count, a high platelet count or a clotting problem and sends a referral, and the patient searches the practice’s name and the word on the lab report before the first visit. Others find the practice on their own, looking for an iron infusion, for a sickle cell care team or for an answer to years of heavy bleeding. Those searches raise the questions this guide answers. Can an ad promise more energy after one iron infusion? Who may say “cure” about sickle cell disease? How should a practice write about a lifelong disease and the pain it brings, with respect? What does “hematologist” mean next to “hematologist-oncologist”? This guide covers what the federal patient pages, the federal statutes and the certifying boards say, and how to turn that into copy and ads.

Three related topics have their own guides and are not repeated here. Cancer claims, oncology patient stories and experimental treatments are covered in our guide to cancer center and oncology advertising. Coverage wording, copay coupons and drug names in Google Ads for infused medicines are covered in our guide to infusion center marketing. Recruiting patients into studies is covered in our guide to clinical trial recruitment ads. This guide covers what is specific to blood disorders that are not cancer, and to the words a hematology practice uses about itself. Practices that manage blood thinners should read anticoagulation clinic marketing, including its bleeding warning sign wording.

This is general information, not legal or medical advice. Sources cited were checked on October 30, 2026: the NHLBI pages on Anemia and Iron-Deficiency Anemia (last updated March 24, 2022), Sickle Cell Disease (last updated December 10, 2025), Sickle Cell Disease Treatment (last updated September 30, 2024) and Bleeding Disorders (last updated August 3, 2023), the FDA news release of December 8, 2023 on the first gene therapies for sickle cell disease, the American Board of Medical Specialties pages on the American Board of Internal Medicine and the American Board of Pediatrics, Google’s personalized advertising policy, 15 U.S.C. 45 and 52, the FTC Health Products Compliance Guidance, 42 U.S.C. 1320a-7b(b), 16 CFR 255.2 and 45 CFR 164.508. Medical advertising rules are also set state by state. Check them with your counsel before a campaign runs.

What the patient pages say about anemia, sickle cell disease and bleeding disorders

The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, publishes the federal patient pages a careful patient reads before a hematology visit. On the three subjects that bring patients to a benign hematology clinic, they say:

The NHLBI page on anemia (last updated March 24, 2022) says anemia develops when the blood produces a lower than normal amount of healthy red blood cells, that it can make a person feel tired or weak, and that it may be a sign of a more serious condition, such as bleeding in the stomach, inflammation from an infection, kidney disease, cancer or autoimmune diseases. It says treatment depends on the type and how serious it is.
The NHLBI page on iron-deficiency anemia (last updated March 24, 2022) lists blood loss and problems absorbing iron among the causes, and says diagnosis uses blood tests that include a complete blood count, hemoglobin, blood iron and ferritin levels.
The NHLBI page on sickle cell disease (last updated December 10, 2025) says it is a group of inherited disorders that affect hemoglobin, that sickled red blood cells can block blood flow and cause sudden episodes of strong pain called pain crises, that it is a lifelong illness that may be managed through preventive screening and treatment, and that with the right care people who have it can live fulfilling lives.
The NHLBI page on bleeding disorders (last updated August 3, 2023) says these disorders affect the way the body controls clotting, that they can be inherited or acquired, that symptoms can include easy bruising, heavy menstrual periods and repeated nosebleeds, and that a provider may recommend precautions before a medical procedure or during a pregnancy even when the disorder itself does not need treatment.

Two points from these pages shape hematology marketing. First, anemia is a finding with a cause, and the cause may be serious, so a page that sells a treatment without the workup leaves out what the federal page puts first. Second, the patients a hematologist sees for sickle cell disease and bleeding disorders live with a condition for life, so a page written for them is a long relationship, not a one-time offer.

Hematologist, hematologist-oncologist and benign hematology

Patients and referring offices read the title before anything else, and the certifying boards define it. The American Board of Medical Specialties page on the American Board of Internal Medicine lists Hematology as a subspecialty and says hematology physicians have additional training and specialize in malignant and non-malignant diseases of the blood, bone marrow, spleen and lymph tissues. It lists Medical Oncology as a separate subspecialty, for physicians who specialize in the diagnosis and treatment of cancer and select benign tumors. The American Board of Medical Specialties page on the American Board of Pediatrics lists Pediatric Hematology-Oncology, for pediatricians trained to recognize and manage pediatric blood disorders and cancerous diseases.

So the words carry a meaning a patient can check. A few rules follow from that:

Write the certificate the way the board words it: “board certified in hematology” or “board certified in hematology and in medical oncology”, with the American Board of Internal Medicine named. Check each physician’s status on the board’s verification tool and update the page when a certificate changes.
“Hematologist-oncologist” tells a patient the physician treats blood cancers and other cancers as well. Use it only where that is true, and do not let a certificate in one subspecialty be read as both.
“Benign hematology” or “non-cancer blood disorders” is a fair way to describe a clinic that sees anemia, clotting and bleeding problems, and sickle cell disease. Say on the page which conditions the clinic sees and which it sends elsewhere, so a patient with a new cancer diagnosis does not book the wrong clinic.
A hematology clinic that sits inside a cancer center can say so. Our guide to physician bio pages and board certification covers bio page wording in general.

Iron infusion claims

Iron infusions are the hematology service patients search for by name, and the claims around them are where hematology copy overreaches. The NHLBI page on iron-deficiency anemia describes iron supplements taken by mouth as a treatment that can take three to six months to restore iron levels, and describes IV iron as a way to put iron into the body through a vein that can restore iron levels in one or a few sessions. It says people with serious iron-deficiency anemia or long-term conditions are more likely to receive IV iron, and lists vomiting or headaches right after treatment as side effects that go away within a day or two. It also says surgery may be needed to stop internal bleeding, and the anemia page lists bleeding in the stomach and cancer among the serious conditions anemia may signal.

Under 15 U.S.C. 45, deceptive acts or practices in commerce are unlawful, and 15 U.S.C. 52 prohibits false advertisements likely to induce the purchase of drugs, devices, services or cosmetics. The FTC staff Health Products Compliance Guidance says claims about the health benefits or safety of health-related products require competent and reliable scientific evidence, and that an advertiser is responsible for the claims a reasonable reader takes away, including implied ones.

Phrases that need rewriting:

“Feel energized after one infusion” or “get your energy back in a day”. The NHLBI page describes restored iron levels, not a felt result on a set day. Write “IV iron can restore iron levels in one or a few sessions, according to the NHLBI. At your visit we explain what to expect and how we check your levels afterward.”
“Skip the pills” or “faster than pills” as a headline. The NHLBI page names both and says who is more likely to receive IV iron. Say the hematologist decides with the patient which fits, after the tests.
“Iron infusions for anyone who feels tired”. Tiredness has causes other than low iron, and the NHLBI page ties diagnosis to blood tests. Write “for patients whose blood tests show iron-deficiency anemia” and describe the workup.
“Fix your anemia in one visit”. The anemia page says the cause matters and may be serious. Say that the practice looks for the cause and works with the referring doctor or a specialist where bleeding or absorption is the problem.
“No side effects” or “completely safe”. The NHLBI page lists side effects. Name them in plain words and say the clinic watches patients during and after the infusion.
“[Town]’s best hematologist”. A superiority claim needs substantiation. Name the physician, their training and their certificates instead.

Do not name drug brands in ads or headlines, and do not state doses. Google’s limits on drug terms in ads are covered in our infusion center guide, and cash pay and drip bar style offers are covered in our guide to IV therapy clinic marketing. A hematology infusion is a medical treatment ordered after a diagnosis; keep the copy in that frame.

Sickle cell disease: “cure”, transplant and gene therapy wording

“Cure” is the word patients and families hope to read, and it is also where a sickle cell page can mislead. The NHLBI page on sickle cell disease treatment (last updated September 30, 2024) describes daily medicines, blood transfusions and pain care as the ongoing treatments, and describes a blood and bone marrow transplant as a potential curative therapy for some people with sickle cell disease. It says a transplant needs a well-matched donor, is riskier in adults, carries risks that include graft-versus-host disease, serious infections, infertility and transplant failure, and that a transplant may not correct all the damage the disease has already caused.

On gene therapy, the FDA news release of December 8, 2023 says the agency approved the first cell-based gene therapies for sickle cell disease, for patients 12 years and older, and that before treatment a patient’s own stem cells are collected and the patient must undergo high-dose chemotherapy. It says blood cancer has occurred in patients treated with one of the two therapies and that its label carries a boxed warning about that risk. The NHLBI treatment page adds that transplants and gene therapies require weeks in a hospital and specialized care, that only a few medical centers offer them for sickle cell disease, and that a person treated with either can still pass the sickle cell gene to their children.

Phrases that need rewriting:

“We cure sickle cell disease” or “sickle cell cure now available”. Use the agencies’ own wording: a transplant is a “potential curative therapy for some people”, in the NHLBI’s words, and the FDA approved gene therapies “to treat” sickle cell disease for patients 12 and older. Say who may be a candidate and that the evaluation decides.
“One-time treatment” with nothing else. The NHLBI page says these treatments are designed to be given once, and the same page describes stem cell collection, chemotherapy and weeks in a hospital. Name all of it together.
“Gene therapy here” for a clinic that refers out. If the clinic evaluates and refers patients to a center that provides transplant or gene therapy, say exactly that. Our guide to stem cell clinic advertising covers unapproved stem cell offers, which are a different thing from an approved transplant.
“Pain-free life”. The NHLBI page describes treatments that reduce or help manage symptoms. Describe the plan, the team and how patients reach the team during a crisis.

Writing about sickle cell disease with respect

Sickle cell copy is read by patients who have spent years explaining their pain. The NHLBI page says pain crises come from blocked blood flow and can require medical attention. A few writing choices follow from that:

Write “people with sickle cell disease” or “patients with sickle cell disease”. Do not use slang names for patients, and do not describe a person as their disease.
Describe pain as the NHLBI does: a symptom of blocked blood flow that can require medical attention. Do not write copy that frames requests for pain care as a problem to be managed.
Say how a patient reaches the team during a crisis, during and after office hours, and tell patients to call 911 in an emergency. Do not imply the clinic replaces an emergency department.
Keep sickle cell trait and sickle cell disease apart. The NHLBI page describes trait as inheriting a sickle cell gene from one parent and disease as inheriting one from each parent. A trait screening page should not read like a disease diagnosis.
Show the whole lifespan if the clinic sees it: children moving into adult care, pregnancy planning and adult follow-up, each with a link to the matching NHLBI page.

Ad targeting needs care too. Google’s personalized advertising policy lists both Health and Race and ethnicity among its sensitive interest categories, and says advertisers promoting products and services in those categories are unable to use advertiser-curated audiences. Reach patients through search terms, location and referring doctors instead, and write ads that make sense to anyone who sees them.

A practice that runs a dedicated sickle cell program has more to plan: emergency wording in every tool, a pain action plan page, the move from pediatric to adult care and drug maker support. Our guide to sickle cell disease center marketing covers those.

Bleeding disorders, heavy periods and referrals

The NHLBI bleeding disorders page lists heavy menstrual periods among the symptoms and says precautions may be needed before a procedure or a pregnancy. That makes gynecologists, obstetricians, surgeons and dentists the referral sources for a bleeding disorder clinic. A page for them should say what the clinic tests, how fast it sees a pre-procedure referral and how it reports back. A page for patients should describe the symptoms in the NHLBI’s words and say a blood test workup comes first; it should not tell a reader they have a bleeding disorder.

Arrangements with the offices that send patients are where the federal Anti-Kickback Statute comes in. 42 U.S.C. 1320a-7b(b) makes it a crime to knowingly and willfully offer or pay anything of value to induce referrals of items or services paid for by federal health care programs. Have counsel review any arrangement that involves value moving to or from a referral source. Our guide to patient and physician referrals covers the marketing side.

Patient stories and photos

A patient story about a care plan that worked makes a strong ad, and results in blood disorders vary with the condition and the person. Our guide to testimonials and before and after photos covers the full rules. The short version: where the practice is a covered entity, a story or photo used to market the practice needs a signed authorization under 45 CFR 164.508. Under 16 CFR 255.2, an ad that shows one patient’s result on a key attribute is likely to be read as what others will generally achieve, unless the practice has substantiation for that or clearly and conspicuously discloses what people can generally expect. Name the condition and the treatment, and say that results vary. A diagnosis named in a caption is health information; treat it that way, and for a child, get the parent’s or guardian’s authorization.

Illustration: two ads for the same hematology practice

Illustration: an ad reads “Tired all the time? One iron infusion and you’ll feel like yourself again. No side effects, skip the pills. Now offering the sickle cell cure. [Town]’s best blood doctor.” It promises a felt result the NHLBI page does not describe, sells a treatment without the workup, denies side effects the federal page lists, uses “cure” for therapies the agencies describe as treatment or as potentially curative for some people, and makes an unsubstantiated superiority claim.

Illustration: a second ad for the same practice reads “Low iron or anemia on your blood test? [Physician name], MD, board certified in hematology, sees adults with anemia, clotting and bleeding problems, and sickle cell disease. We look for the cause, explain iron by mouth and IV iron, and work with your doctor. Sickle cell patients: a care plan and a team you can reach. We check your benefits before treatment and tell you what we find.” It describes the workup first, names the exact credential, and makes no cure or energy promise.

Checklist before a hematology campaign goes live

Condition pages match the NHLBI pages, with links and dates, and say that the cause of anemia is looked for before treatment.
No page or ad promises more energy, a fix in one visit, or no side effects from an iron infusion.
“Cure” appears only in the NHLBI’s or FDA’s own wording, with the date, the eligibility and the risks.
Transplant and gene therapy pages say whether the clinic provides them or refers patients to a center that does.
Each physician’s certificates are named exactly as the board’s verification record shows them, and “hematologist-oncologist” is used only where it is true.
No drug brands or doses appear in ads or headlines.
Sickle cell pages use person-first wording, describe pain as a symptom that can require care, give the crisis contact path and the 911 line, and keep trait and disease apart.
Ads target by search terms and location, not by health or race and ethnicity audiences.
Referral source arrangements have been reviewed by counsel.
Each story and photo used in marketing has a signed authorization, names the condition and treatment, and says results vary.

How we help

We build websites, local search, Google Ads and AI front desk tools for independent practices and health businesses, including physician specialty practices. For a hematology practice, that means condition pages that follow the NHLBI pages with links and dates, physician bios with certificates worded the way the boards word them, iron infusion ads without energy or no side effect promises, and referral and appointment forms that keep lab results and diagnoses away from tracking tools. We do not decide which treatments are offered or how care is delivered; your clinicians, your counsel and your state boards do. Our tools are built with HIPAA in mind. We confirm in writing what a BAA covers before any patient information flows through a tool, and if it is not covered, we do not route patient information through it. We are not a healthcare provider and we do not give legal or medical advice. We do not sell lead lists and we do not pay for referrals. For the wider rules, see our healthcare marketing rules hub.

Can we advertise that an iron infusion restores energy?

Avoid it. The NHLBI page on iron-deficiency anemia describes IV iron as a way to restore iron levels in one or a few sessions. It does not describe a felt result on a set day. Describe what the treatment does to iron levels and how the clinic checks them afterward.

Can we say iron infusions have no side effects?

No. The NHLBI page lists vomiting or headaches right after treatment as side effects that go away within a day or two. Name the side effects and say the clinic watches patients during and after the infusion.

Can a hematology practice say it cures sickle cell disease?

Not as a general claim. The NHLBI describes a blood and bone marrow transplant as a potential curative therapy for some people with sickle cell disease, with serious risks, and the FDA approved gene therapies to treat sickle cell disease in patients 12 years and older. Use that wording, say who may be a candidate, and say whether the clinic provides the treatment or refers patients to a center that does.

What is the difference between a hematologist and a hematologist-oncologist?

The American Board of Medical Specialties page on the American Board of Internal Medicine lists Hematology and Medical Oncology as separate subspecialties. A physician certified in both can describe themselves as board certified in hematology and in medical oncology. Name the certificates as the board’s verification record shows them.

Can we target ads to the communities sickle cell disease affects?

Not through advertiser-curated audiences. Google’s personalized advertising policy lists Health and Race and ethnicity among its sensitive interest categories. Use search terms, location and referring doctors, and write ads that make sense to anyone who sees them.

Should a bleeding disorder page talk about heavy periods?

Yes, in the NHLBI’s words. Its bleeding disorders page lists heavy menstrual periods among the symptoms. Say that a blood test workup comes first and do not tell a reader they have a bleeding disorder.

Hematology practice marketing: anemia and iron infusion claims, sickle cell cure wording and board titles